Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia
Date
2014
Authors
Jabbour, E.J.
Hughes, T.P.
Cortés, J.E.
Kantarjian, H.M.
Hochhaus, A.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Leukemia and Lymphoma, 2014; 55(7):1451-1462
Statement of Responsibility
Elias J. Jabbour, Timothy P. Hughes, Jorge E. Cortés, Hagop M. Kantarjiaa, Andreas Hochhaus
Conference Name
Abstract
Despite vast improvements in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase (CP), advanced stages of CML, accelerated phase or blast crisis, remain notoriously difficult to treat. Treatments that are highly effective against CML-CP produce disappointing results against advanced disease. Therefore, a primary goal of therapy should be to maintain patients in CP for as long as possible, by (1) striving for deep, early molecular response to treatment; (2) using tyrosine kinase inhibitors that lower risk of disease progression; and (3) more closely observing patients who demonstrate cytogenetic risk factors at diagnosis or during treatment.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2014 Informa UK, Ltd